Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07823790
PHASE2
ONO-4915 in Patients With Primary Sjogren's Disease
Sponsor: Ono Pharmaceutical Co., Ltd.
View on ClinicalTrials.gov
Summary
To evaluate the efficacy and safety of ONO-4915 in patients with primary Sjogren's disease
Official title: A Phase II Multicenter, Placebo-controlled, Randomized, Double-blind, Parallel-group Study in Patients With Primary Sjogren's Disease to Evaluate the Efficacy and Safety of Subcutaneously Administered ONO-4915
Key Details
Gender
All
Age Range
18 Years - 74 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2026-10
Completion Date
2029-02
Last Updated
2026-09-16
Healthy Volunteers
No
Conditions
Interventions
DRUG
ONO-4915
Subcutaneous administration
DRUG
Placebo
Subcutaneous administration